 | Up a level |
Sabatine, Marc S., Leiter, Lawrence A., Wiviott, Stephen D., Giugliano, Robert P., Deedwania, Prakash, De Ferrari, Gaetano M., Murphy, Sabina A., Kuder, Julia F., Gouni-Berthold, Ioanna, Lewis, Basil S., Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C., Sever, Peter S. and Pedersen, Terje R. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol., 5 (12). S. 941 - 951. NEW YORK: ELSEVIER SCIENCE INC. ISSN 2213-8587